Mefenamic acid (Ponstan Paediatric, Ponstan)
Mefenamic acid
Pfizer Laboratories (Pty) Ltd
Registration
- Applicant
- Pfizer Laboratories (Pty) Ltd
- Registrations
- 3
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ponstan paediatric suppositories EACH SUPPOSITORY CONTAINS MEFENAMIC ACID 125 mg | Suppositories | 27056127/2.7/0561 | Registered | Not determined | None |
| Ponstan capsules CAPSULE MEFENAMIC ACID 250 MG | Capsules | B0560B/2.7/560 | Registered | Not determined | None |
| Ponstan suspension 5 ML MEFENAMIC ACID 50 MG | Suspension | B0561B/2.7/561 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Mefenamic acid
- when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; and
- preparations containing mefenamic acid as the only therapeutic active substance, when intended for human use only in the treatment of primary dysmenorrhoea subject to a maximum daily dose of 500 millligrams mefenamic acid 3 times a day and a maximum treatment period of 3 days. (S2)
Consolidated Schedules 06 July 2026, lines 3915 to 3921
S2: Mefenamic acid
- when intended for the treatment of post-traumatic conditions, for a maximum treatment period of 5 days; and
- preparations containing mefenamic acid as the only therapeutically active substance, when intended for human use only in the treatment of primary dysmenorrhoea, subject to a maximum daily dose of 500 millligrams 3 times a day and a maximum treatment period of 3 days; (S3)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 2271 to 2280
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
2-(2,3-Dimethylanilino)benzoic acid
Drag to rotate. Structure from PubChem CID 4044.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.